Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar) in Adult Patients With Uveal Melanoma and Metastatic Dissemination (O-Mel-Sora)

Trial Profile

Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar) in Adult Patients With Uveal Melanoma and Metastatic Dissemination (O-Mel-Sora)

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Uveal melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jun 2016 Primary endpoint has been met. (non-tumor progression rate), as per an article published in the British Journal of Cancer.
    • 02 Jun 2016 Status changed from active, no longer recruiting to completed, as per an article published in the British Journal of Cancer.
    • 02 Jun 2016 Results published in the British Journal of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top